PharmAla Biotech's Positive Growth and Key Developments

PharmAla Biotech Reports Strong Financial Results and Key Developments

PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a prominent biotechnology company, is proud to unveil its audited financial statements and significant operational milestones. The Company focuses on the innovative research, development, and manufacturing of LaNeo™ MDMA and its derivatives. This announcement highlights the financial performance and strategic initiatives that underscore the Company’s growth trajectory.

Financial Performance Overview

For the year ending August 31, 2024, PharmAla showcased a robust financial performance, reporting revenue exceeding $1 million. This marks an impressive year-over-year growth of approximately 95%, largely driven by an increase in MDMA product sales, which surged by $723,000.

CEO Nick Kadysh remarked on the Company’s ability to navigate challenges while building a solid foundation for future growth. The integration of new talent, such as CFO Will Avery, signifies PharmAla's commitment to maintaining its momentum in an ever-evolving market.

Notable Financial Highlights

The Company achieved remarkable milestones throughout the fiscal year:

• Revenue growth of $503,000, highlighting the potential for sustained increase in sales.
• An Adjusted EBITDA improvement to ($55,000), showcasing a $605,000 enhancement from the prior year, primarily driven by rising revenues.
• Granting of patents for innovative MDXX molecules, APA-01 and ALA-002, instituting the Company's strategic edge in the market.
• The successful generation of $772,000 in net proceeds from share issuances, which indicates strong market confidence in its initiatives.

Company Expansion Through Continuance

In a strategic move, PharmAla has transitioned its governance from British Columbia to Ontario, effective December 17, 2024. This continuance was enthusiastically supported by shareholders during the annual general meeting. The shift denotes a pivotal moment for PharmAla, creating opportunities for enhanced operational efficiencies and broader market reach.

Importantly, existing shareholders can rest assured that no additional actions are required regarding this transition.

Successful Private Placement

The Company is also thrilled to announce the completion of its non-brokered private placement offering, raising aggregate gross proceeds of approximately $1.56 million. The offering included the sale of 8,676,221 Units and was oversubscribed by 12%, reflecting the strong interest among investors.

Each Unit, priced at $0.18, comprises one Common Share and one-half Warrant to purchase additional shares at a price of C$0.27. These funds will play a crucial role in advancing PharmAla’s objectives, including securing global patent rights for its innovative products and funding clinical trials.

Strategic Vision and Future Outlook

PharmAla is committed to alleviating the backlog of clinical-grade MDMA, making it accessible for clinical trials and commercial applications. The Company stands out as a pioneer, provisioning clinical-grade MDMA outside of formal trials, setting a precedent within the industry.

Will Avery, CFO of PharmAla, expressed optimism regarding the future, stating, “Our focus on quality and continued product sales growth positions us well for the upcoming year.”

About PharmAla

Founded on the core vision of transforming the biotechnology landscape, PharmAla Biotech Holdings Inc. is dedicated to developing MDXX class molecules, including MDMA. The organization strives to establish strong regulatory relationships and innovate in clinical-grade MDMA, facilitating its use in patient treatments.

For further inquiries, you may contact:
Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website: www.PharmAla.ca

Frequently Asked Questions

What is PharmAla's main focus?

PharmAla primarily focuses on the research, development, and manufacturing of LaNeo™ MDMA and its derivatives.

How much revenue did PharmAla generate in fiscal 2024?

The Company generated over $1 million in revenue, indicating a 95% increase compared to the previous year.

What recent developments has PharmAla achieved?

PharmAla successfully obtained patents for two new MDXX molecules and completed a major private placement to support future initiatives.

What strategic changes has PharmAla made recently?

PharmAla completed its continuance from British Columbia to Ontario, enhancing its governance and operational framework.

Who leads PharmAla Biotech?

PharmAla is led by CEO Nicholas Kadysh and CFO Will Avery, both of whom emphasize innovation and quality within the organization.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.